Nanjing Qingpu Biotechnology Co., Ltd is a company that focuses on the development of pain management solutions. With its extensive research and development expertise and unique formulation technology, the company aims to enhance existing pain medications and create innovative, improved analgesics for both the Chinese and American markets.

Tags

Nervous System Diseases

Other Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	5
Infectious Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

TRPV1(Transient receptor potential cation channel subfamily V member 1)	1
COX-1 x COX-2	1

Drugs associated with Nanjing Qingpu Biotechnology Co., Ltd.

Meloxicam

Target

COX-1 x COX-2

Mechanism

COX-1 inhibitors [+1]

Active Org.

Avondale Pharmaceuticals LLC [+9]

Originator Org.

Cali Biosciences Co. Ltd. [+1]

Active Indication

Juvenile Idiopathic Arthritis [+10]

Inactive Indication

Abdominal Pain [+8]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1998

QP-6211

Target-

Mechanism-

Active Org.

Nanjing Qingpu Biotechnology Co., Ltd.Startup

Originator Org.

Nanjing Qingpu Biotechnology Co., Ltd.Startup

Active Indication

Pain, Postoperative

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

QP002

Target-

Mechanism-

Active Org.

Nanjing Qingpu Biotechnology Co., Ltd.Startup

Originator Org.

Nanjing Qingpu Biotechnology Co., Ltd.Startup

Active Indication

Pain, Postoperative [+1]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Nanjing Qingpu Biotechnology Co., Ltd.

CTR20241317 / RecruitingPhase 1

一项评价注射用QP-6211单次给药在健康志愿者的安全性、耐受性、药代动力学特征和药效动力学特征的单中心、随机、双盲、阳性药和安慰剂平行对照、剂量爬坡的I期研究

[Translation] A single-center, randomized, double-blind, active- and placebo-controlled, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of a single dose of QP-6211 for injection in healthy volunteers

评价健康志愿者中QP-6211单次给药后的安全性、耐受性、PK、PD特征

[Translation]

To evaluate the safety, tolerability, PK, and PD characteristics of QP-6211 after a single dose in healthy volunteers

Start Date19 Apr 2024

Sponsor / Collaborator

Nanjing Qingpu Biotechnology Co., Ltd.Startup

CTR20240548 / RecruitingPhase 2

一项评价QP002凝胶单次给药用于单侧全髋关节置换手术受试者的有效性、安全性和药代动力学特征的多中心、随机、双盲、阳性药和安慰剂平行对照的研究

[Translation] A multicenter, randomized, double-blind, active and placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetic characteristics of a single dose of QP002 gel in subjects undergoing unilateral total hip replacement surgery

评价QP002单次给药用于单侧全髋关节置换术术后镇痛的有效性、安全性和药代动力学特征（PK），探索合理剂量。

[Translation]

To evaluate the efficacy, safety, and pharmacokinetic characteristics (PK) of a single dose of QP002 for postoperative analgesia in unilateral total hip replacement surgery and to explore the appropriate dose.

Start Date26 Mar 2024

Sponsor / Collaborator

Nanjing Qingpu Biotechnology Co., Ltd.Startup

CTR20231667 / RecruitingPhase 2

多中心、随机、双盲、平行对照评价QP002用于拇外翻矫形手术受试者的有效性、安全性和药代动力学特征研究

[Translation] A multicenter, randomized, double-blind, parallel controlled study to evaluate the efficacy, safety and pharmacokinetic characteristics of QP002 in subjects undergoing hallux valgus correction surgery

评价QP002用于拇外翻矫形手术受试者的安全性和有效性、药代动力学特征、探索合理剂量。

[Translation]

To evaluate the safety, efficacy, pharmacokinetic characteristics and explore the appropriate dosage of QP002 in subjects undergoing hallux valgus correction surgery.

Start Date25 Jun 2023

Sponsor / Collaborator

Nanjing Qingpu Biotechnology Co., Ltd.Startup

100 Clinical Results associated with Nanjing Qingpu Biotechnology Co., Ltd.

0 Patents (Medical) associated with Nanjing Qingpu Biotechnology Co., Ltd.

Literatures (Medical) associated with Nanjing Qingpu Biotechnology Co., Ltd.

01 Oct 2023·Inflammopharmacology

Preemptive QP001, a fast-acting meloxicam formulation, provides analgesia and reduces opioid consumption following abdominal surgery: a randomized controlled trial.

Article

Author: Gao, Yuanli ; Jiang, Yan ; Zhang, Ying ; Wu, Ziteng ; Xu, Mingjun ; Shen, Yufei ; Dai, Ruping ; Li, Jiangang ; Zhang, Wei ; Wang, Bin ; Duan, Kaiming ; Wang, Saiying ; Yang, Mengchang ; Yu, Sen ; Hu, Xianwen ; Zhou, Yingyong ; Bai, Zhihong ; Ouyang, Wen ; Li, Xiaohong

BACKGROUNDQP001, a novel meloxicam formulation, has been developed to manage moderate to severe postoperative pain. This study aimed to evaluate the efficacy and safety of QP001 injections for moderate to severe pain following abdominal surgery.METHODThis prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial enlisted patients experiencing moderate to severe pain following abdominal surgery. These patients were randomized to receive either QP001 injections (30 mg or 60 mg) or a placebo pre-surgery. The primary efficacy endpoint was the total morphine consumption within 24 h after the first administration.RESULTSA total of 108 patients were enrolled, and 106 patients completed the study. The total morphine consumption in the QP001 30 mg group and 60 mg group, versus placebo group, were significantly lower over the following 24 h (5.11[5.46] vs 8.86[7.67], P = 0.011; 3.11[3.08] vs 8.86[7.67], P < 0.001), respectively. The total morphine consumption in the QP001 30 mg and 60 mg groups, versus placebo group, was also significantly decreased over the following 48 h, including the 24-48 h period (P ≤ 0.001). The QP001 30 mg and 60 mg groups, versus placebo, showed a significant decrease in the area under the curve for pain intensity-time as well as a significant decrease in the effective pressing times of the analgesic pump over the 24 h and 48 h periods (P < 0.05). The QP001 groups, versus placebo, show no significant different in Adverse Events or Adverse Drug Reactions (P > 0.05).CONCLUSIONPreoperative/preemptive QP001 provides analgesia and reduces opioid consumption in patients with moderate to severe pain following abdominal surgery, while maintaining a favorable safety profile.

01 Jan 2023·Drug design, development and therapy

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Novel Intravenous Formulation of Meloxicam (QP001) in Healthy Chinese Subjects.

Article

Author: Yang, Shuang ; Zhang, Xuqing ; Li, Mingyuan ; Wu, Ziteng ; Yang, Xiaoyan ; Ma, Junlong ; Huang, Jie ; Jiang, Yan ; Zou, Chan ; Yang, Guoping ; Yu, Sen ; Xie, Jinlian ; Zhang, Xingfei ; Wu, Qian

BackgroundMeloxicam is a selective cyclooxygenase-2 inhibitor used for pain relief, but its poor solubility limits its clinical applications. QP001 is a novel intravenous formulation of meloxicam developed with PEG and pH regulator to improve its solubility. This study aimed to evaluate the safety, tolerability, and pharmacokinetics of QP001 in Chinese healthy subjects.MethodsThe trial consisted of three parts. Part I was a two-period crossover study to evaluate bioavailability, in which 10 healthy were either intravenously infused with 15mg QP001 (test) or orally given 15mg Mobic^Ⓡ (reference). Part II was a single-arm design to assess the pharmacokinetic (PK) characteristics after 30 mg single- and multiple-dose QP001 in 10 subjects. In part III, we investigated the PKs and tolerability of QP001 at a high dose (60 mg) in another 10 subjects. The PK parameters and treatment-emergent adverse events (TEAEs) were evaluated.ResultsA total of 30 subjects were enrolled in the study. QP001 was well tolerated and safe without significant TEAEs in all three study parts. The PK characteristics of QP001 were linear following a single-dose range of 15-60 mg (C_max and AUC_0-t were 5.82-17.66 μg/mL and 58.08-251.17 μg∙h/mL, respectively). After five consecutive daily 30 mg doses, the accumulation index was around 1.98, which indicated a minimal accumulation of QP001. Compared to the tablet dosage form, the relative bioavailability of QP001 reached 116.85%. Additionally, the PK profile of QP001 showed no gender difference.ConclusionQP001 was well tolerated in healthy Chinese subjects after single ascending doses up to 60 mg and multiple-dose of 30 mg. Based on the PK and safety results, QP001 is a promising once-daily intravenous COX-2 inhibitor candidate for managing pain.Trial RegistrationThe trial is registered at chinadrugtrials.org.cn (ChiCTR2100047884).

Preemptive QP001 provides analgesia and reduces opioid consumption in subjects with moderate to severe pain following abdominal surgery: a randomized controlled trial

Author: Gao, Yuanli ; Zhang, Ying ; Wu, Ziteng ; Xu, Mingjun ; Shen, Yufei ; Dai, Ruping ; Li, Jiangang ; Zhang, Wei ; Yu, Sen ; Zhou, YingYong ; Wang, Saiying ; Wang, Bin ; Duan, Kaiming ; Ouyang, Wen ; Yang, Mengchang ; Hu, Xianwen ; Bai, Zhihong ; Jiang, Yan ; Li, Xiaohong

AbstractBackground QP001, a novel meloxicam formulation, has been developed to manage moderate to severe postoperative pain. This study aimed to evaluate the efficacy and safety of QP001 injections for moderate to severe pain following abdominal surgery. Method This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial enlisted patients experiencing moderate to severe pain following abdominal surgery. These patients were randomized to receive either QP001 injections (30mg or 60mg) or a placebo pre-surgery. The primary efficacy endpoint was the total morphine consumption within 24 hours after the first administration. Results A total of 108 patients were enrolled, and 106 patients completed the study. The total morphine consumption in the QP001 30mg group and 60mg group were significantly lower than that in the placebo group within 24 hours after the first administration (mean [SD] 5.11[5.46] vs 8.86[7.67], P = 0.011; 3.11[3.08] vs 8.86[7.67], P < 0.001). Compared with the placebo group, the total morphine consumption in the QP001 30mg and 60mg groups significantly decreased within 48 hours and 24–48 hours after the first administration (P ≤ 0.001); the area under curve of pain intensity-time and the effective pressing times of analgesic pump within 24 h and 48 h after the first administration was significantly reduced (P < 0.05). The QP001 groups did not show more Adverse Events and Adverse Drug Reactions than the placebo group(P > 0.05). Conclusion Preemptive QP001 provides analgesia and reduces opioid consumption in subjects with moderate to severe pain following abdominal surgery, while maintaining a favorable safety profile.

100 Deals associated with Nanjing Qingpu Biotechnology Co., Ltd.

100 Translational Medicine associated with Nanjing Qingpu Biotechnology Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

IND Application

Phase 2 Clinical

NDA/BLA

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Meloxicam ( COX-1 x COX-2 )	-	NDA/BLA
QP002	Pain, Postoperative More	Phase 2
QP-6211	Pain, Postoperative More	Phase 2
QP-5113 ( TRPV1 )	-	IND Application
QP004	Pain, Postoperative More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis